The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics

被引:177
作者
Bak, Annette [1 ]
Gore, Anu [2 ]
Yanez, Evelyn [2 ]
Stanton, Mary [1 ]
Tufekcic, Sunita [1 ]
Syed, Rashid [3 ]
Akrami, Anna [4 ]
Rose, Mark [4 ]
Surapaneni, Sekhar [4 ]
Bostick, Tracy [5 ]
King, Anthony [5 ]
Neervannan, Sesha [2 ]
Ostovic, Drazen [2 ]
Koparkar, Arun [2 ]
机构
[1] Amgen Inc, Dept Pharmaceut, Cambridge, MA 02139 USA
[2] Amgen Inc, Dept Pharmaceut, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Mol Struct, Thousand Oaks, CA 91320 USA
[4] Amgen Inc, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[5] Amgen Inc, Chem Res & Dev, Thousand Oaks, CA 91320 USA
关键词
co-crystals; bioavailability; physicochemical properties; physical stability; physical characterization;
D O I
10.1002/jps.21280
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Co-crystals are relatively novel in the pharmaceutical field and are not reported extensively. AMG 517 is an insoluble small molecule VR1 (vanilloid receptor 1) antagonist. In animal studies, good exposure of AMG 517 is seen from a 10% (w/v) Pluxonic (R) F108 in OraPlus (R) suspension. Investigation of the suspension formulation revealed that AMG 517 forms a co-crystal with sorbic acid, a preservative in OraPlus (R). This co-crystal of AMG 517 was isolated by coslurrying AMG 517 and sorbic acid; studied by DSC and XRD; and identified by solution NMR, TGA, and HPLC to be a 1:1 association of AMG 517 and sorbic acid. Single crystal structure analysis revealed a 1:1 co-crystal of AXIG 517 and sorbic acid, held together by two hydrogen bonds and other noncovalent, nonionic forces. The co-crystal has better aqueous solubility initially as compared to AMG 517 free base but does revert back to a form of the free base hydrate during prolonged slurry in FaSIF (fasted simulated intestinal fluid). Pharmacokinetic evaluation of the co-crystal in rats using 10% (w/v) Pluronic F108 (R) in OraPlus (R) suspensions revealed that a 30 mg/kg dose in suspension had comparable exposure to a 500 mg/kg dose of the free base. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:3942 / 3956
页数:15
相关论文
共 36 条
[1]  
*ACD, 1994, ADV CHEM DEV SOFTW S
[2]   SYSTEMATIC ANALYSIS OF STRUCTURAL DATA AS A RESEARCH TECHNIQUE IN ORGANIC-CHEMISTRY [J].
ALLEN, FH ;
KENNARD, O ;
TAYLOR, R .
ACCOUNTS OF CHEMICAL RESEARCH, 1983, 16 (05) :146-153
[3]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[4]  
BEASLEY MW, 2004, HDB PHARM EXCIPIENTS, P588
[5]   Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid [J].
Chen, Alex M. ;
Ellison, Martha E. ;
Peresypkin, Andrey ;
Wenslow, Robert M. ;
Variankaval, Narayan ;
Savarin, Cecile G. ;
Natishan, Theresa K. ;
Mathre, David J. ;
Dormer, Peter G. ;
Euler, Danielle H. ;
Ball, Richard G. ;
Ye, Zhixiong ;
Wang, Yaling ;
Santos, Ivan .
CHEMICAL COMMUNICATIONS, 2007, (04) :419-421
[6]   Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids [J].
Childs, SL ;
Chyall, LJ ;
Dunlap, JT ;
Smolenskaya, VN ;
Stahly, BC ;
Stahly, GP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (41) :13335-13342
[7]  
COOKE MW, 2007, IWPCPS 9 9 INT WORKS
[8]   Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate [J].
Doherty, Elizabeth M. ;
Fotsch, Christopher ;
Bannon, Anthony W. ;
Bo, Yunxin ;
Chen, Ning ;
Dominguez, Celia ;
Falsey, James ;
Gavva, Narender R. ;
Katon, Jodie ;
Nixey, Thomas ;
Ognyanov, Vassil I. ;
Pettus, Liping ;
Rzasa, Robert M. ;
Stec, Markian ;
Surapaneni, Sekhar ;
Tamir, Rami ;
Zhu, Jiawang ;
Treanor, James J. S. ;
Norman, Mark H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (15) :3515-3527
[9]   Crystal and co-crystal: a second opinion [J].
Dunitz, JD .
CRYSTENGCOMM, 2003, 5 :506-506
[10]   Crystal engineering of the composition of pharmaceutical phases:: Multiple-component crystalline solids involving carbamazepine [J].
Fleischman, SG ;
Kuduva, SS ;
McMahon, JA ;
Moulton, B ;
Walsh, RDB ;
Rodríguez-Hornedo, N ;
Zaworotko, MJ .
CRYSTAL GROWTH & DESIGN, 2003, 3 (06) :909-919